TP53 and cancer: Finally, translational progress is bottlenecked by the lack of strategies to selectively manipulate p53’s ferroptosis-regulating activity: activating its pro-ferroptotic function in cancer cells while preserving its anti-ferroptotic role in normal tissues remains a major challenge, and no validated biomarkers exist to predict which tumors will respond to p53-targeted ferroptosis therapies.